Clinical Trial Update: Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on Hsp90 inhibitor AUY922 combined with erlotinib in stage IIIB-IV non-small cell lung cancer; study completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AUY922 (luminespib)
• Erlotinib hydrochloride (Erlotinib)

Snippet

Sponsor: Northwestern University | Conditions: Adenocarcinoma of the Lung, Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-11-21